Skip to content

Advances in Motion

Tricuspid Valve Repair and Tricuspid Valve Replacement Successfully Performed at Mass General

Article

Originally published in Mass General

In This Article

  • A tricuspid valve replacement and tricuspid valve repair were performed at Massachusetts General Hospital earlier this summer as part of two clinical trials
  • The hospital was the first in New England to perform these new procedures
  • Dr. Sammy Elmariah, principal investigator for both studies, said that the procedures may improve patients' quality of life and reduce or eliminate symptoms

Tricuspid valve disease currently affects more than 1.6 million Americans, but each year, only a few hundred patients undergo open-heart surgery to correct the condition. Symptoms of tricuspid valve disease—including fluid retention, shortness of breath and abnormal heart rhythms—are often treated with medications alone, leading to progression of disease and worsening of side effects and long-term complications.

In August 2020, Massachusetts General Hospital announced two first-of-their-kind procedures in New England to treat tricuspid valve disease: tricuspid valve replacement and tricuspid valve repair. Sammy Elmariah, MD, MPH, director of Interventional Cardiology Research in the Corrigan Minehan Heart Center at Mass General and principal investigator for the studies of both new procedures, said that the new procedures bring exciting new options to patients who have long had limited treatment options and who have been suffering from tricuspid valve disease.

In both tricuspid valve repair and tricuspid valve replacement, the heart's tricuspid valve is accessed by the care team through the femoral vein in the leg, with patients discharged in a matter of days following the procedure.

Both procedures have been performed at Mass General as part of the nationwide CLASP II TR Trial and the TRISCEND Early Feasibility Study. Enrollment for both studies is nearly complete, and Mass General will continue to have an active role in clinical testing of valve replacement technology with the forthcoming TRISCEND II Clinical Trial.

Read More on Mass General

Learn more about the Heart Valve Program at Mass General

Refer a patient to the Corrigan Minehan Heart Center

Related topics

Related

Pulmonary hypertension was common in patients with severe mitral valve regurgitation and was associated with increased mortality and readmissions for heart failure after transcatheter mitral valve repair.

Cardiovascular, Hypertension, Interventional Cardiology, Pulmonary and Critical Care, Valvular Heart Disease

Journal

Related

The first study to examine whether hospital volume of percutaneous coronary interventions is associated with the outcomes of structural heart procedures found no association between the two metrics.

Aortic Disease, Cardiovascular, Interventional Cardiology, Valvular Heart Disease

Journal